{"id":"vaginal-estrogen-twice-weekly","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Vaginal discharge"},{"rate":"5-10%","effect":"Vaginal itching"},{"rate":"5-10%","effect":"Breast tenderness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vaginal estrogen works by releasing estrogen directly into the vagina, which helps to restore the natural balance of estrogen in the body. This can help to alleviate symptoms such as vaginal dryness, itching, and burning, as well as hot flashes and night sweats. The exact mechanism is not fully understood, but it is thought to involve the stimulation of estrogen receptors in the vagina and surrounding tissues.","oneSentence":"Estrogen replacement therapy to alleviate menopausal symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:29.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment"},{"name":"Treatment of vaginal pain during sexual intercourse"}]},"trialDetails":[{"nctId":"NCT05457972","phase":"PHASE4","title":"Postpartum Vaginal Estrogen for Breastfeeding Patients","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2025-02-22","conditions":"Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy","enrollment":100},{"nctId":"NCT05317364","phase":"PHASE4","title":"Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2022-07-14","conditions":"Obstetric; Injury Pelvic Floor, Sexual Dysfunction, Anal Incontinence","enrollment":38},{"nctId":"NCT06780163","phase":"PHASE4","title":"Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2025-06-27","conditions":"Overactive Bladder (OAB), Menopause, Microbiome","enrollment":30},{"nctId":"NCT06353269","phase":"PHASE4","title":"Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2024-06-14","conditions":"Recurrent Urinary Tract Infection, Hypoestrogenism","enrollment":111},{"nctId":"NCT06873971","phase":"NA","title":"Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause","status":"RECRUITING","sponsor":"University of Nove de Julho","startDate":"2025-12-10","conditions":"Genitourinary Syndrome of Menopause","enrollment":60},{"nctId":"NCT07186985","phase":"NA","title":"The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence","status":"NOT_YET_RECRUITING","sponsor":"Hanoi Medical University","startDate":"2025-11-01","conditions":"Stress Urinary Incontinence (SUI), Postmenopausal Women","enrollment":115},{"nctId":"NCT05562518","phase":"PHASE4","title":"GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2022-03-21","conditions":"Vulvovaginal Atrophy, Breast Cancer","enrollment":160},{"nctId":"NCT05472779","phase":"PHASE2","title":"Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"Stephanie Wang Zuo","startDate":"2023-01-03","conditions":"Recurrent Urinary Tract Infection","enrollment":114},{"nctId":"NCT07030426","phase":"PHASE3","title":"Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery","status":"NOT_YET_RECRUITING","sponsor":"Queen's University","startDate":"2025-10-01","conditions":"Pelvic Organ Prolapse (POP)","enrollment":180},{"nctId":"NCT07038070","phase":"NA","title":"Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-07-01","conditions":"Genitourinary Syndrome of Menopause (GSM)","enrollment":196},{"nctId":"NCT06197295","phase":"PHASE4","title":"Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Urinary Bladder, Overactive, Effect of Drug","enrollment":200},{"nctId":"NCT06479720","phase":"PHASE4","title":"Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","status":"RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2022-06-16","conditions":"Effect of Drug, Urinary Bladder, Overactive","enrollment":300},{"nctId":"NCT05483634","phase":"","title":"Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","status":"NOT_YET_RECRUITING","sponsor":"Mackay Memorial Hospital","startDate":"2025-12-01","conditions":"Menopause, Platelet-rich Plasma, Estrogen Replacement Therapy","enrollment":40},{"nctId":"NCT06508944","phase":"PHASE4","title":"Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2024-04-08","conditions":"Lower Urinary Tract Symptoms, Female Genitourinary Disease, Urinary Stress Incontinence","enrollment":86},{"nctId":"NCT06654570","phase":"PHASE2","title":"Effects of Vaginal Estrogen on Serum Estradiol During Aromatase Inhibitor Therapy in Breast Cancer Patients with Vulvovaginal Atrophy: a Prospective Trial","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2020-04-08","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT01648751","phase":"NA","title":"Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse","status":"TERMINATED","sponsor":"Pamela Moalli","startDate":"2012-05","conditions":"Pelvic Organ Prolapse","enrollment":21},{"nctId":"NCT06425978","phase":"PHASE4","title":"Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit","status":"RECRUITING","sponsor":"Fundación Santiago Dexeus Font","startDate":"2024-05-30","conditions":"Genitourinary Syndrome of Menopause","enrollment":192},{"nctId":"NCT04301934","phase":"NA","title":"Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-06-01","conditions":"Urinary Tract Infections","enrollment":12},{"nctId":"NCT06031493","phase":"PHASE4","title":"A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2025-01","conditions":"Cervical Cancer, Sexual Dysfunction, Quality of Life","enrollment":122},{"nctId":"NCT04544475","phase":"NA","title":"A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-09-01","conditions":"Genitourinary Syndrome of Menopause (GSM)","enrollment":49},{"nctId":"NCT05458375","phase":"EARLY_PHASE1","title":"Vaginal Estradiol Use in Pessary Care","status":"TERMINATED","sponsor":"University of South Florida","startDate":"2022-12-29","conditions":"Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina","enrollment":11},{"nctId":"NCT02213757","phase":"PHASE4","title":"Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2014-08","conditions":"Microscopic Hematuria","enrollment":29},{"nctId":"NCT03943823","phase":"PHASE4","title":"Postmenopausal Pessary Users: Estrogen Versus Trimosan","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-05-07","conditions":"Vaginosis, Vaginosis, Bacterial, Vaginal Discharge","enrollment":4},{"nctId":"NCT05651087","phase":"NA","title":"Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient","status":"UNKNOWN","sponsor":"Gun Oh Chong","startDate":"2022-12-20","conditions":"Hormone Receptor-positive Breast Cancer","enrollment":60},{"nctId":"NCT04606550","phase":"NA","title":"MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study","status":"WITHDRAWN","sponsor":"Mount Sinai Hospital, Canada","startDate":"2021-09-01","conditions":"Breast Cancer Female, Genitourinary Syndrome of Menopause","enrollment":""},{"nctId":"NCT03996057","phase":"PHASE4","title":"Methenamine in a Non-antibiotic, Multimodal Approach to UTI Prevention","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2018-06-20","conditions":"UTI, Female Urogenital Diseases, UTI - Lower Urinary Tract Infection","enrollment":""},{"nctId":"NCT03493126","phase":"PHASE4","title":"Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2018-10-15","conditions":"Vaginal Atrophy","enrollment":59},{"nctId":"NCT02835846","phase":"PHASE4","title":"Investigation of the Effect of the Female Urinary Microbiome on Incontinence","status":"COMPLETED","sponsor":"Loyola University","startDate":"2016-09","conditions":"Overactive Bladder, Incontinence, Nocturia","enrollment":35},{"nctId":"NCT02869165","phase":"PHASE4","title":"Vaginal and Urinary Microbiome Trial","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2017-01","conditions":"Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections","enrollment":110},{"nctId":"NCT02524769","phase":"NA","title":"The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides","status":"COMPLETED","sponsor":"Loyola University","startDate":"2015-12","conditions":"Overactive Bladder","enrollment":27},{"nctId":"NCT03779633","phase":"PHASE4","title":"Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2017-02-02","conditions":"Pelvic Organ Prolapse","enrollment":120},{"nctId":"NCT04393194","phase":"PHASE4","title":"The Effect of Intra-vaginal Conjugated Estrogen Cream on Ring Pessary Use for Pelvic Organ Prolapse","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-05-24","conditions":"Pelvic Floor Prolapse","enrollment":420},{"nctId":"NCT02691936","phase":"NA","title":"Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2016-03","conditions":"Atrophic Vaginitis, Menopause","enrollment":69},{"nctId":"NCT01843166","phase":"NA","title":"Vaginal Estrogen With Pessary Treatment","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Vaginal Infection, Urinary Tract Infection, Quality of Life","enrollment":150},{"nctId":"NCT03018106","phase":"PHASE4","title":"Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction","status":"TERMINATED","sponsor":"Emory University","startDate":"2017-06-30","conditions":"Sexual Dysfunction, Physiological","enrollment":1},{"nctId":"NCT00816556","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis","status":"TERMINATED","sponsor":"Maire Mac Bride","startDate":"2008-10","conditions":"Atrophic Vaginitis","enrollment":63},{"nctId":"NCT01613170","phase":"PHASE4","title":"Premarin Versus Toviaz for Treatment of Overactive Bladder","status":"UNKNOWN","sponsor":"The Cleveland Clinic","startDate":"2012-04","conditions":"Overactive Bladder","enrollment":90},{"nctId":"NCT00361569","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2006-08","conditions":"Menopause","enrollment":622}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Conjugated Estrogens CSD, 0.625 mg/g, Vaginal Cream"],"phase":"phase_3","status":"active","brandName":"Vaginal Estrogen - Twice Weekly","genericName":"Vaginal Estrogen - Twice Weekly","companyName":"Queen's University","companyId":"queen-s-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Estrogen replacement therapy to alleviate menopausal symptoms. Used for Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause or breast cancer treatment, Treatment of vaginal pain during sexual intercourse.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}